{"id":183171,"name":"SUMITOMO PHARMA AMERICA, INC. (FORMERLY SUNOVION PHARMACEUTICALS INC.)","slug":"sumitomo-pharma-america-inc-formerly-sunovion-pharmaceuticals-inc","state":"MA","country":"United States of America","description":"","totalSpending":7490000,"filings":25,"yearlySpending":[{"year":2018,"income":1290000},{"year":2019,"income":1310000},{"year":2020,"income":1140000},{"year":2021,"income":1140000},{"year":2022,"income":1310000},{"year":2023,"income":1090000},{"year":2024,"income":210000}],"issues":["HCR"],"firms":["SUMITOMO PHARMA AMERICA, INC.(FORMERLY SUNOVION PHARMACEUTICALS INC.)"],"lobbyists":["ERIC RASMUSSEN","BELA SASTRY","THERESA JOLIVETTE"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Office of Management & Budget (OMB)","Centers For Medicare and Medicaid Services (CMS)"],"sampleDescriptions":["Discussions regarding protected classes reform\nPart D proposed rule and LIS co-pays\nPart B Payment reform\nMassachusetts 1115 Medicaid waiver amendment\nFDA Regulatory Review\nOpioid Substance Abuse legi","Discussions regarding protected classes reform\nPart B drug coverage and Payment reform\nMassachusetts 1115 Medicaid waiver amendment\nFDA Regulatory Review\nOpioid Substance Abuse legislation\nMedicare Pa","Discussions regarding protected classes reform, Medicare Part D\nPart B drug coverage and Payment reform\nOpioid Substance Abuse legislation\nMedicare Part D Coverage Gap provisions in Bipartisan Budget ","Discussions regarding protected classes reform, Medicare Part D\nPart B drug coverage and Payment reform; international pricing index model\nMedicare Part D Coverage Gap provisions in Bipartisan Budget ","Discussions regarding protected classes reform, Medicare Part D\nPart B drug coverage and Payment reform; international pricing index model\nMedicare Part D Negotiation/Non-Interference Repeal Bills\nPri"],"years":[2018,2019,2020,2021,2022,2023,2024]}